Last reviewed · How we verify
IMM27M
At a glance
| Generic name | IMM27M |
|---|---|
| Sponsor | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors (PHASE1)
- Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMM27M CI brief — competitive landscape report
- IMM27M updates RSS · CI watch RSS
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. portfolio CI